Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18686041 | RECOMBINANT PROTEIN OF NERVE GROWTH FACTOR MUTANT AND USE THEREOF | February 2024 | January 2026 | Abandon | 22 | 2 | 1 | No | No |
| 18540403 | Methods of Treating a Spastic Disorder in a Subject Having Underlying Condition(s) | December 2023 | February 2025 | Abandon | 14 | 2 | 1 | No | No |
| 18525736 | NOVEL ANTI-A2AP ANTIBODIES AND USES THEREOF | November 2023 | September 2024 | Allow | 10 | 1 | 1 | No | No |
| 18521777 | Methods of Treating an Optic Disease in a Subject | November 2023 | November 2025 | Abandon | 24 | 2 | 1 | No | Yes |
| 18455179 | Methods of Treating Cervical Dystonia in a Subject Having Underlying Condition(s) | August 2023 | December 2025 | Abandon | 28 | 3 | 1 | No | No |
| 18359633 | Methods of Treating or Preventing Migraine or Repetitive Occurrence of Common Migraine Headaches in a Subject Having Underlying Condition(s) | July 2023 | January 2025 | Abandon | 18 | 3 | 1 | No | No |
| 17853108 | ANTI-SECRETOGRANIN III (SCG3) ANTIBODIES AND USES THEREOF | June 2022 | March 2026 | Abandon | 45 | 0 | 1 | No | No |
| 17850383 | CGRP ANTAGONISTS AND CLOSTRIDIAL DERIVATIVES FOR THE TREATMENT OF NEUROPSYCHIATRIC AND NEUROLOGICAL DISORDERS | June 2022 | January 2026 | Abandon | 42 | 0 | 1 | No | No |
| 17686734 | INCREASING ATOH1 LIFE TO DRIVE SENSORINEURAL HAIR CELL DIFFERENTIANTION | March 2022 | January 2026 | Allow | 46 | 1 | 0 | No | No |
| 17613310 | NOROVIRUS-BINDING PEPTIDE | November 2021 | September 2025 | Allow | 46 | 0 | 1 | Yes | No |
| 17481528 | Method of Treating Peripheral Nerve Disorders | September 2021 | April 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17391990 | COMPOSITIONS AND METHODS FOR DETERMINING CORONAVIRUS NEUTRALIZATION TITERS | August 2021 | March 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17384408 | SINGLE CHAIN INTRABODIES THAT ALTER HUNTINGTIN MUTANT DEGRADATION | July 2021 | January 2026 | Allow | 54 | 1 | 1 | Yes | No |
| 17242780 | ANTIBODY BASED REAGENTS THAT SPECIFICALLY RECOGNIZE NEURODEGENERATIVE DISEASE RELATED FORMS OF THE PROTEIN TDP-43 | April 2021 | January 2025 | Allow | 45 | 1 | 0 | Yes | No |
| 17126351 | METHOD OF EFFECTING NEUROPROTECTION USING SOLUBLE NEUREGULIN ISOFORMS | December 2020 | December 2025 | Abandon | 60 | 2 | 1 | No | No |
| 17051635 | ANTI-CARBONIC ANHYDRASE IX ANTIBODY | October 2020 | April 2025 | Allow | 54 | 1 | 1 | Yes | No |
| 17051413 | TREATMENT OF MELANOMA BRAIN METASTASIS BY INHIBITION OF AMYLOID PRECURSOR PROTEIN CLEAVAGE | October 2020 | November 2024 | Abandon | 48 | 2 | 1 | No | No |
| 17041050 | METHOD FOR DIFFERENTIATING MOTOR NEURONS FROM TONSIL-DERIVED MESENCHYMAL STEM CELLS | September 2020 | September 2025 | Abandon | 60 | 3 | 1 | No | No |
| 17013974 | METHODS FOR THE IDENTIFICATION, ASSESSMENT, PREVENTION, AND TREATMENT OF NEUROLOGICAL DISORDERS AND DISEASES | September 2020 | June 2025 | Abandon | 57 | 2 | 1 | No | No |
| 17012159 | METHOD OF EFFECTING NEUROPROTECTION USING SOLUBLE NEUREGULIN ISOFORMS | September 2020 | January 2025 | Allow | 52 | 1 | 1 | No | No |
| 16769743 | ANTIBODIES, COMPOSITIONS FOR USE IN DETECTING OR CAPTURING A POLYPEPTIDE IN A SAMPLE, AND METHODS FOR DETECTING OR CAPTURING A POLYPEPTIDE IN A SAMPLE | June 2020 | May 2025 | Allow | 60 | 3 | 1 | No | No |
| 16768187 | BODY FLUID ANTIBODY BIOMARKER FOR HIGHLY SENSITIVE DETECTION OF RISK OF ONSET OF CEREBRAL INFARCTION | May 2020 | August 2025 | Allow | 60 | 4 | 1 | Yes | No |
| 16755312 | SYSTEMS AND METHODS FOR PRODUCING RETINAL PROGENITORS | April 2020 | October 2024 | Allow | 54 | 2 | 1 | No | No |
| 16782094 | CLADRIBINE REGIMEN FOR TREATING MULTIPLE SCLEROSIS | February 2020 | February 2023 | Allow | 36 | 1 | 1 | No | No |
| 16634869 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASE, CONTAINING, AS ACTIVE INGREDIENTS, CYCLODEXTRIN AND STEM CELLS IN WHICH VEGF IS OVEREXPRESSED | January 2020 | September 2025 | Abandon | 60 | 5 | 1 | Yes | No |
| 16612141 | GUT MICROBIOME FUNCTION PREDICTS RESPONSE TO ANTI-INTEGRIN BIOLOGIC THERAPY IN INFLAMMATORY BOWEL DISEASES | November 2019 | June 2025 | Abandon | 60 | 3 | 1 | Yes | No |
| 16512278 | STEM CELL MODEL OF APOE GENOTYPE AND Abeta42-DEPENDENT NEURODEGENERATION AND METHODS OF USING THE SAME | July 2019 | November 2024 | Abandon | 60 | 3 | 1 | No | No |
| 16457267 | MONOVALENT BLOOD BRAIN BARRIER SHUTTLE MODULES | June 2019 | July 2021 | Allow | 24 | 1 | 1 | Yes | No |
| 16447106 | RE-USE OF ENZYMES IN IN VITRO GLYCOENGINEERING OF ANTIBODIES | June 2019 | December 2024 | Allow | 60 | 3 | 1 | Yes | No |
| 16329659 | METHODS AND COMPOSITIONS FOR SPINAL CORD CELLS | February 2019 | December 2025 | Abandon | 60 | 7 | 1 | No | No |
| 16119656 | CYCLIN-DEPENDENT KINASE 5 (CDK5) INHIBITORY PEPTIDES | August 2018 | April 2025 | Allow | 60 | 4 | 1 | Yes | No |
| 15781681 | COMPOSITIONS AND METHODS FOR INTERNALIZING ENZYMES | June 2018 | June 2025 | Abandon | 60 | 7 | 1 | Yes | No |
| 15772572 | METHOD FOR VACCINATION AGAINST A SELF-ANTIGEN IN A HUMAN PATIENT | May 2018 | March 2025 | Allow | 60 | 5 | 1 | Yes | Yes |
| 15768736 | MICROFLUIDIC MODEL OF THE BLOOD BRAIN BARRIER | April 2018 | May 2025 | Abandon | 60 | 7 | 0 | No | No |
| 15352289 | DEVELOPMENT OF SPINAL CORD ON A MICROFLUIDIC CHIP | November 2016 | February 2024 | Allow | 60 | 7 | 0 | Yes | No |
| 15352249 | MODULATING THE PRODUCTION OF NEURONS AND/OR OLIGODENDROCYTES FROM WHITE MATTER PROGENITOR CELLS | November 2016 | June 2019 | Allow | 31 | 2 | 1 | Yes | No |
| 15034766 | VH4 ANTIBODIES AGAINST GRAY MATTER NEURON AND ASTROCYTE | May 2016 | September 2018 | Abandon | 28 | 3 | 1 | No | No |
| 15012141 | SCREENING METHODS FOR COGNITIVE ENHANCERS | February 2016 | August 2017 | Allow | 19 | 1 | 0 | Yes | No |
| 14863541 | CELLULAR TRANSPLANT SITE | September 2015 | June 2019 | Allow | 44 | 3 | 1 | Yes | No |
| 14505845 | IN VITRO MODEL FOR NEURONAL DEATH | October 2014 | August 2016 | Allow | 22 | 1 | 1 | Yes | No |
| 14122116 | VEGF-D/VEGFR2/3-Mediated Regulation of Dendrites | November 2013 | June 2016 | Allow | 30 | 2 | 1 | Yes | No |
| 13975414 | PEPTIDES AND METHODS USING SAME FOR DIAGNOSIS AND TREATMENT OF AMYLOID-ASSOCIATED DISEASE | August 2013 | November 2014 | Allow | 15 | 1 | 1 | Yes | No |
| 13841351 | Sp35 Antibodies and Uses Thereof | March 2013 | March 2015 | Allow | 24 | 2 | 1 | Yes | No |
| 13718788 | TREATING NEUROLOGICAL DISORDERS | December 2012 | June 2017 | Allow | 54 | 3 | 1 | Yes | Yes |
| 13595130 | USE OF ENDOGENOUS ANTIOXIDANT PROTEINS IN THE TREATMENT OF STROKE | August 2012 | September 2017 | Allow | 60 | 4 | 1 | Yes | No |
| 13400244 | CYTOKINE ANTAGONISTS FOR NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | February 2012 | October 2012 | Allow | 7 | 0 | 0 | Yes | No |
| 13364504 | SCREENING METHODS FOR COGNITIVE ENHANCERS | February 2012 | February 2014 | Allow | 25 | 1 | 1 | Yes | No |
| 13128004 | DENDRITIC CELL MODULATION IN POST-ISCHEMIC WOUNDS | November 2011 | September 2015 | Allow | 53 | 2 | 1 | Yes | No |
| 13181387 | COMPOSITION COMPRISING VARIOUS PROTEORHODOPSINS AND/OR BACTERIORHODOPSINS AND USE THEREOF | July 2011 | October 2012 | Allow | 15 | 1 | 1 | Yes | No |
| 13018300 | HUMAN G-PROTEIN CHEMOKINE RECEPTOR HSATU68 | January 2011 | September 2014 | Allow | 43 | 2 | 1 | Yes | No |
| 12223197 | Method for the Treatment and/or Prophylaxis of Multiple Sclerosis, and Use of Erythropoietin for the Manufacture of a Medicament for the Intermittent Treatment and/or Intermittent Prophylaxis of Multiple Sclerosis | January 2011 | September 2015 | Allow | 60 | 3 | 1 | Yes | No |
| 12601803 | APROTININ-LIKE POLYPEPTIDES FOR DELIVERING AGENTS CONJUGATED THERETO TO TISSUES | August 2010 | February 2016 | Allow | 60 | 3 | 1 | Yes | No |
| 12450515 | ISOLATED POPULATION OF CELLS AND METHODS OF GENERATING AND USING SAME | May 2010 | March 2015 | Allow | 60 | 2 | 1 | No | No |
| 12767164 | REGENERATION AND NEOGENESIS OF RETINAL PHOTORECEPTOR CELL USING OTX2 GENE | April 2010 | January 2012 | Allow | 21 | 1 | 1 | No | No |
| 12730587 | Biomarkers for Assessing Peripheral Neuropathy Response to Cancer Treatment | March 2010 | November 2016 | Allow | 60 | 5 | 1 | No | No |
| 12714068 | USE OF SCF AND G-CSF IN THE TREATMENT OF CEREBRAL ISCHEMIA AND NEUROLOGICAL DISORDERS | February 2010 | April 2013 | Allow | 38 | 1 | 0 | No | No |
| 12688287 | NEUREGULINS FOR PREVENTION AND TREATMENT OF DAMAGE FROM ACUTE ASSAULT ON VASCULAR AND NEURONAL TISSUE AND AS REGULATORS OF NEURONAL STEM CELL MIGRATION | January 2010 | July 2011 | Allow | 18 | 2 | 0 | Yes | No |
| 12688351 | NEUREGULINS FOR PREVENTION AND TREATMENT OF DAMAGE FROM ACUTE ASSAULT ON VASCULAR AND NEURONAL TISSUE AND AS REGULATORS OF NEURONAL STEM CELL MIGRATION | January 2010 | May 2011 | Allow | 16 | 1 | 0 | Yes | No |
| 12590989 | PROTEIN MARKERS ASSOCIATED WITH BONE MARROW STEM CELL DIFFERENTIATION INTO EARLY PROGENITOR DENDRITIC CELLS | November 2009 | September 2012 | Allow | 34 | 2 | 1 | No | No |
| 12568661 | METHODS TO FACILITATE TRANSMISSION OF LARGE MOLECULES ACROSS THE BLOOD-BRAIN, BLOOD-EYE, AND BLOOD-NERVE BARRIERS | October 2009 | March 2012 | Allow | 30 | 1 | 1 | Yes | No |
| 12305088 | IN VITRO MULTIPARAMETER DETERMINATION METHOD FOR THE DIAGNOSIS AND EARLY DIAGNOSIS OF NEURODEGENERATIVE DISORDERS | September 2009 | August 2014 | Allow | 60 | 3 | 1 | Yes | Yes |
| 12458163 | PEPTIDES DIRECTED FOR DIAGNOSIS AND TREATMENT OF AMYLOID-ASSOCIATED DISEASES | July 2009 | December 2010 | Allow | 17 | 1 | 0 | No | No |
| 12474229 | DISC-1 PATHWAY ACTIVATORS IN THE CONTROL OF NEUROGENESIS | May 2009 | December 2011 | Allow | 31 | 0 | 2 | Yes | No |
| 12437167 | EYE-DROP VACCINE CONTAINING COPOLYMER 1 FOR THERAPEUTIC IMMUNIZATION | May 2009 | July 2014 | Allow | 60 | 2 | 1 | Yes | Yes |
| 12406925 | HUMAN BRAIN CARBOXYPEPTIDASE B | March 2009 | February 2011 | Allow | 23 | 1 | 1 | Yes | No |
| 12368838 | MODULATING THE PRODUCTION OF NEURONS AND/OR OLIGODENDROCYTES FROM WHITE MATTER PROGENITOR CELLS | February 2009 | September 2014 | Allow | 60 | 4 | 1 | Yes | No |
| 12359851 | NEUREGULINS FOR PREVENTION AND TREATMENT OF DAMAGE FROM ACUTE ASSAULT ON VASCULAR AND NEURONAL TISSUE AND AS REGULATORS OF NEURONAL STEM CELL MIGRATION | January 2009 | September 2014 | Allow | 60 | 3 | 1 | Yes | No |
| 12359773 | NEUREGULINS FOR PREVENTION AND TREATMENT OF DAMAGE FROM ACUTE ASSAULT ON VASCULAR AND NEURONAL TISSUE AND AS REGULATORS OF NEURONAL STEM CELL MIGRATION | January 2009 | June 2014 | Allow | 60 | 5 | 1 | Yes | No |
| 12353196 | METHODS FOR IDENTIFYING SUBSTANCES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | January 2009 | September 2010 | Allow | 20 | 2 | 0 | Yes | No |
| 12263939 | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF SCHIZOPHRENIA | November 2008 | September 2011 | Allow | 35 | 1 | 1 | Yes | No |
| 12253428 | STIMULATING NEURITE OUTGROWTH USING TCTEX-1-RELATED POLYPEPTIDES | October 2008 | January 2012 | Allow | 39 | 0 | 1 | Yes | No |
| 11814906 | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF SCHIZOPHRENIA | September 2008 | August 2011 | Allow | 49 | 2 | 1 | Yes | No |
| 12177100 | ASSAY FOR PARKINSON'S DISEASE THERAPEUTICS | July 2008 | May 2011 | Allow | 34 | 2 | 1 | No | No |
| 12143202 | CELLS AND METHODS FOR ESTIMATION OF EFFECTS ON NEUROLOGICAL DYSFUNCTION | June 2008 | September 2009 | Allow | 15 | 0 | 0 | No | No |
| 12136509 | USE OF EPO RECEPTOR ACTIVATION OR STIMULATION FOR THE IMPROVEMENT OF THE EDSS SCORE IN PATIENTS WITH MULTIPLE SCLEROSIS | June 2008 | June 2015 | Allow | 60 | 6 | 1 | Yes | No |
| 12080212 | STEM CELL FACTOR-LIKE PROTEINS AND USES THEREOF | April 2008 | October 2009 | Allow | 18 | 0 | 0 | No | No |
| 12042165 | DIRS1 POLYPEPTIDES | March 2008 | December 2009 | Allow | 21 | 0 | 1 | No | No |
| 12065523 | Method for Quantifying a Cholinergic Neurotoxin in a Sample | March 2008 | July 2015 | Allow | 60 | 3 | 1 | Yes | No |
| 11569862 | COMPOSITION COMPRISING VARIOUS PROTEORHODOPSINS AND/OR BACTERIORHODOPSINS AND USE THEREOF | December 2007 | March 2011 | Allow | 51 | 2 | 1 | Yes | No |
| 11892036 | SP35 ANTIBODIES AND USES THEREOF | August 2007 | June 2013 | Allow | 60 | 5 | 1 | Yes | No |
| 11891335 | METHODS AND SYSTEMS FOR NEURAL MAINTENANCE AND REGENERATION | August 2007 | September 2012 | Allow | 60 | 2 | 0 | No | No |
| 11571479 | OPTIMIZED INTERFERON-BETA GENE | June 2007 | August 2009 | Allow | 32 | 2 | 1 | No | No |
| 11687302 | DOSING REGIMENS FOR NEURAL STEM CELL PROLIFERATING AGENTS AND DIFFERENTIATING AGENTS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | March 2007 | November 2011 | Allow | 56 | 6 | 1 | Yes | No |
| 11601799 | METHODS TO FACILITATE TRANSMISSION OF LARGE MOLECULES ACROSS THE BLOOD-BRAIN, BLOOD-EYE, AND BLOOD-NERVE BARRIERS | November 2006 | August 2009 | Allow | 33 | 1 | 1 | Yes | No |
| 11514352 | NEUREGULINS FOR PREVENTION AND TREATMENT OF DAMAGE FROM ACUTE ASSAULT ON VASCULAR AND NEURONAL TISSUE AND AS REGULATORS OF NEURONAL STEM CELL MIGRATION | September 2006 | June 2010 | Allow | 45 | 4 | 2 | Yes | No |
| 11484719 | METHODS AND KITS FOR DIAGNOSING AND TREATING MENTAL RETARDATION | July 2006 | August 2009 | Allow | 37 | 3 | 1 | No | No |
| 11428122 | TCTEX-1-RELATED POLYPEPTIDES | June 2006 | May 2008 | Allow | 23 | 1 | 1 | No | No |
| 11479173 | DUAL BENEFICIAL EFFECT OF DOPAMINE ENHANCING AND NEUROPROTECTIVE ACTIONS OF PKC DELTA INHIBITORS FOR TREATMENT OF PARKINSON'S DISEASE | June 2006 | September 2013 | Allow | 60 | 2 | 1 | Yes | No |
| 11473196 | PREVENTION OF DEFICITS IN NEUROGENESIS WITH ANTI-INFLAMMATORY AGENTS | June 2006 | March 2011 | Allow | 57 | 4 | 2 | No | Yes |
| 11446875 | ANTI-TRKB MONOCLONAL ANTIBODIES AND USES THEREOF | June 2006 | November 2009 | Allow | 42 | 1 | 1 | No | No |
| 11442314 | CELLS AND METHODS FOR ESTIMATION OF EFFECTS ON NEUROLOGICAL DYSFUNCTION | May 2006 | April 2008 | Allow | 22 | 2 | 1 | No | No |
| 11359489 | METHOD OF DETECTING OR DIAGNOSING OF A NEURODEGENERATIVE DISEASE OR CONDITION | February 2006 | March 2010 | Allow | 49 | 4 | 1 | Yes | No |
| 11336237 | PRESERVING HYPOXIC TISSUE | January 2006 | June 2010 | Allow | 53 | 2 | 1 | No | Yes |
| 11334081 | STEM CELL FACTOR-LIKE PROTEINS AND USES THEREOF | January 2006 | January 2008 | Allow | 24 | 1 | 1 | No | No |
| 10559784 | Method for producing retinal neurocyte from neural stem cell derived from iris tissue | December 2005 | August 2013 | Allow | 60 | 4 | 1 | No | No |
| 10559783 | Method for producing tissue cells from pluripotent stem cells derived from iris pigment epithelial cells of animal and tissue cell obtained by method | December 2005 | April 2014 | Allow | 60 | 8 | 1 | Yes | No |
| 11290293 | METHOD OF DIMINISHING THE SYMPTOMS OF NEURODEGENERATIVE DISEASE | November 2005 | August 2009 | Allow | 45 | 4 | 1 | Yes | No |
| 11283005 | ANTIBODIES TO PROTEIN MARKERS ASSOCIATED WITH BONE MARROW STEM CELL DIFFERENTIATION INTO EARLY PROGENITOR DENDRITIC CELLS | November 2005 | August 2009 | Allow | 45 | 3 | 1 | No | No |
| 11262528 | CYTOKINE ANTAGONISTS FOR NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | October 2005 | December 2011 | Allow | 60 | 4 | 2 | Yes | No |
| 10549707 | MONOCYTE-ORIGIN MULTIPOTENT CELL MOMC | October 2005 | May 2010 | Allow | 56 | 6 | 1 | Yes | Yes |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner DUTT, ADITI.
With a 100.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 23.1% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner DUTT, ADITI works in Art Unit 1675 and has examined 106 patent applications in our dataset. With an allowance rate of 87.7%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 51 months.
Examiner DUTT, ADITI's allowance rate of 87.7% places them in the 67% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by DUTT, ADITI receive 2.64 office actions before reaching final disposition. This places the examiner in the 77% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by DUTT, ADITI is 51 months. This places the examiner in the 4% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +20.5% benefit to allowance rate for applications examined by DUTT, ADITI. This interview benefit is in the 64% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 26.4% of applications are subsequently allowed. This success rate is in the 44% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 40.7% of cases where such amendments are filed. This entry rate is in the 62% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 133.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 85% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 81.2% of appeals filed. This is in the 74% percentile among all examiners. Of these withdrawals, 61.5% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 64.0% are granted (fully or in part). This grant rate is in the 69% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 12.3% of allowed cases (in the 95% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 4.3% of allowed cases (in the 78% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.